{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:07:41Z","timestamp":1783897661027,"version":"3.55.0"},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pulmonary arterial hypertension (PH), a progressive, incurable, and deadly disease, predominantly develops in women. Growing body of evidence suggest that dysregulated estradiol (E2) metabolism influences the development of PH and that some of the biological effects of E2 are mediated by its major non-estrogenic metabolite, 2-metyhoxyestradiol (2ME). The objective of this study was to examine effects of 2ME in chronic hypoxia (CH)-induced PH and alpha-naphthylthiourea (ANTU)-induced acute lung injury and PH. In addition, we investigated the effects of exposure to different levels of CH on development of PH. Chronic exposure to 15% or 10% oxygen produced similar increases in right ventricle peak systolic pressure (RVPSP) and pulmonary vascular remodeling, but oxygen concentration-dependent increase in hematocrit. Notably, right ventricle (RV) hypertrophy correlated with level of hypoxia and hematocrit, rather than with magnitude of RVPSP. The latter suggests that, in addition to increased afterload, hypoxia (via increased hematocrit) significantly contributes to RV hypertrophy in CH model of PH. In CH-PH rats, preventive and curative 2ME treatments reduced both elevated RVPSP and pulmonary vascular remodeling. Curative treatment with 2ME was more effective in reducing hematocrit and right ventricular hypertrophy, as compared to preventive treatment. Single ANTU injection produced lung injury, i.e., increased lungs weight and induced pleural effusion. Treatment with 2ME significantly reduced pleural effusion and, more importantly, eliminated acute mortality induced by ANTU (33% vs 0%, ANTU vs. ANTU+2ME group). Chronic treatment with ANTU induced PH and RV hypertrophy and increased lungs weight. 2-ME significantly attenuated severity of disease (i.e., reduced RVPSP, RV hypertrophy and pulmonary vascular injury). This study demonstrates that 2ME has beneficial effects in chronic hypoxia- and acute lung injury-induced PH and provides preclinical justification for clinical evaluation of 2ME in pulmonary hypertension.<\/jats:p>","DOI":"10.2478\/prilozi-2021-0003","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T13:57:55Z","timestamp":1619531875000},"page":"41-51","source":"Crossref","is-referenced-by-count":3,"title":["2-Methoxyestradiol Attenuates the Development and Retards the Progression of Hypoxia-And Alpha-Naphthylthiourea-Induced Pulmonary Hypertension"],"prefix":"10.2478","volume":"42","author":[{"given":"Stevan P.","family":"Tofovic","sequence":"first","affiliation":[{"name":"Heart, Lung, Blood and Vascular Medicine Institute , University of Pittsburgh School of Medicine , Pittsburgh , Pennsylvania , USA"},{"name":"Department of Pharmacology and Chemical Biology , University of Pittsburgh School of Medicine , Pittsburgh , Pennsylvania , USA"},{"name":"Department of Medicine , University of Pittsburgh School of Medicine , Pittsburgh , Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Chemical Biology , University of Pittsburgh School of Medicine , Pittsburgh , Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Chemical Biology , University of Pittsburgh School of Medicine , Pittsburgh , Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Petru\u0161evska","sequence":"additional","affiliation":[{"name":"Department of Pathology , University St Cyril and Methods School of Medicine , Skopje , Republic of North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"2026071211372960533_j_prilozi-2021-0003_ref_001_w2aab3b7b6b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. Benza, R.L., et al., An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest, 2012. 142(2): p. 448-456.10.1378\/chest.11-146022281797","DOI":"10.1378\/chest.11-1460"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_002_w2aab3b7b6b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. Escribano-Subias, P., et al., Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J, 2012. 40(3): p. 596-603.10.1183\/09031936.0010121122362843","DOI":"10.1183\/09031936.00101211"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_003_w2aab3b7b6b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. Jing, Z.C., et al., Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest, 2007. 132(2): p. 373-9.10.1378\/chest.06-291317400671","DOI":"10.1378\/chest.06-2913"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_004_w2aab3b7b6b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. Tamura, Y., et al., Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. Circ J, 2017. 82(1): p. 275-282.10.1253\/circj.CJ-17-013928747612","DOI":"10.1253\/circj.CJ-17-0139"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_005_w2aab3b7b6b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. Batton, K.A., et al., Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease. Biol Sex Differ, 2018. 9(1): p. 15.10.1186\/s13293-018-0176-8590745029669571","DOI":"10.1186\/s13293-018-0176-8"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_006_w2aab3b7b6b1b6b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. Chung, L., et al., Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest, 2014. 146(6): p. 1494-1504.10.1378\/chest.13-3014425161324992469","DOI":"10.1378\/chest.13-3014"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_007_w2aab3b7b6b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. Tofovic, S.P., et al., Estradiol metabolites attenuate monocrotaline-induced pulmonary hyper-tension in rats. J Cardiovasc Pharmacol, 2005. 46(4): p. 430-7.10.1097\/01.fjc.0000175878.32920.1716160593","DOI":"10.1097\/01.fjc.0000175878.32920.17"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_008_w2aab3b7b6b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. Tofovic, S.P., et al., 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol, 2006. 45(6): p. 358-67.10.1016\/j.vph.2006.05.00716872912","DOI":"10.1016\/j.vph.2006.05.007"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_009_w2aab3b7b6b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. Tofovic, S.P., et al., 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul Pharmacol, 2009. 51(2-3): p. 190-7.10.1016\/j.vph.2009.06.002276030019540933","DOI":"10.1016\/j.vph.2009.06.002"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_010_w2aab3b7b6b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. Tofovic, S.P., Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol, 2010. 56(6): p. 696-708.10.1097\/FJC.0b013e3181f9ea8d302783920881610","DOI":"10.1097\/FJC.0b013e3181f9ea8d"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_011_w2aab3b7b6b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. Austin, E.D., et al., Gender, sex hormones and pulmonary hypertension. Pulm Circ, 2013. 3(2): p. 294-314.10.4103\/2045-8932.114756375782424015330","DOI":"10.4103\/2045-8932.114756"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_012_w2aab3b7b6b1b6b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. Tofovic, S.P. and E.K. Jackson, Estradiol Metabolism: Crossroads in Pulmonary Arterial Hyper-tension. Int J Mol Sci, 2019. 21(1).10.3390\/ijms21010116698232731877978","DOI":"10.3390\/ijms21010116"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_013_w2aab3b7b6b1b6b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. Austin, E.D., et al., Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J, 2009. 34(5): p. 1093-9.10.1183\/09031936.00010409374212419357154","DOI":"10.1183\/09031936.00010409"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_014_w2aab3b7b6b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. Kawut, S.M., et al., Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest, 2009. 135(3): p. 752-759.10.1378\/chest.08-1758283478518849396","DOI":"10.1378\/chest.08-1758"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_015_w2aab3b7b6b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. Kawut, S.M., et al., Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med, 2017. 195(3): p. 360-368.10.1164\/rccm.201605-1024OC","DOI":"10.1164\/rccm.201605-1024OC"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_016_w2aab3b7b6b1b6b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. Ventetuolo, C.E., et al., Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men. Am J Respir Crit Care Med, 2016. 193(10): p. 1168-75.10.1164\/rccm.201509-1785OC487266526651504","DOI":"10.1164\/rccm.201509-1785OC"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_017_w2aab3b7b6b1b6b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. Ventetuolo, C.E., et al., Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur Respir J, 2016. 47(2): p. 553-63.10.1183\/13993003.01083-2015483113526647441","DOI":"10.1183\/13993003.01083-2015"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_018_w2aab3b7b6b1b6b1ab1ac18Aa","doi-asserted-by":"crossref","unstructured":"18. Tofovic, S.P. and E.K. Jackson, Complexities of oestradiol pharmacology in pulmonary arterial hypertension. Eur Respir J, 2013. 41(6): p. 1465-6.10.1183\/09031936.0016491223728411","DOI":"10.1183\/09031936.00164912"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_019_w2aab3b7b6b1b6b1ab1ac19Aa","doi-asserted-by":"crossref","unstructured":"19. Tofovic, S.P. and E.K. Jackson, Estrogens in Men: Another Layer of Complexity of Estradiol Metabolism in Pulmonary Hypertension. Am J Respir Crit Care Med, 2016. 193(10): p. 1087-90.10.1164\/rccm.201512-2541ED487267327174480","DOI":"10.1164\/rccm.201512-2541ED"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_020_w2aab3b7b6b1b6b1ab1ac20Aa","doi-asserted-by":"crossref","unstructured":"20. Tofovic, S.P.a.J., E.K., 2-Methoxyestradiol in Pulmonary Arterial Hypertension: A New Disease Modifier, in Pulmonary Circulation and Ventilation. 2019, IntechOpen.10.5772\/intechopen.86812","DOI":"10.5772\/intechopen.86812"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_021_w2aab3b7b6b1b6b1ab1ac21Aa","unstructured":"21. Kay, J.M., Effect of intermittent normoxia on chronic hypoxic pulmonary hypertension, right ventricular hypertrophy, and polycythemia in rats. Am Rev Respir Dis, 1980. 121(6): p. 993-1001."},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_022_w2aab3b7b6b1b6b1ab1ac22Aa","doi-asserted-by":"crossref","unstructured":"22. Swigart, R.H., Polycythemia and Right Ventricular Hypertrophy. Circ Res, 1965. 17: p. 30-8.10.1161\/01.RES.17.1.3014302550","DOI":"10.1161\/01.RES.17.1.30"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_023_w2aab3b7b6b1b6b1ab1ac23Aa","doi-asserted-by":"crossref","unstructured":"23. Naeije, R. and C. Dedobbeleer, Pulmonary hypertension and the right ventricle in hypoxia. Exp Physiol, 2013. 98(8): p. 1247-56.10.1113\/expphysiol.2012.06911223625956","DOI":"10.1113\/expphysiol.2012.069112"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_024_w2aab3b7b6b1b6b1ab1ac24Aa","unstructured":"24. Tofovic SP, Z.X., Jones T,Jackson EK, Petrusevska G., 2-Methoxyestradiol attenuates the development and retards the progression of chronic hypoxia-induced pulmonary hypertension in rats. Circulation, 2005. 112: p. 98-99."},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_025_w2aab3b7b6b1b6b1ab1ac25Aa","doi-asserted-by":"crossref","unstructured":"25. Hao, S., et al., 2-Methoxyestradiol attenuates chronic-intermittent-hypoxia-induced pulmonary hypertension through regulating microRNA-223. J Cell Physiol, 2019. 234(5): p. 6324-6335.10.1002\/jcp.2736330246291","DOI":"10.1002\/jcp.27363"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_026_w2aab3b7b6b1b6b1ab1ac26Aa","doi-asserted-by":"crossref","unstructured":"26. Docherty, C.K., M. Nilsen, and M.R. MacLean, Influence of 2-Methoxyestradiol and Sex on Hypoxia-Induced Pulmonary Hypertension and Hypoxia-Inducible Factor-1-alpha. J Am Heart Assoc, 2019. 8(5): p. e011628.10.1161\/JAHA.118.011628647494030819028","DOI":"10.1161\/JAHA.118.011628"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_027_w2aab3b7b6b1b6b1ab1ac27Aa","unstructured":"27. Tofovic, S.P., T. Jones, and G. Petrusevska, Dose-dependent therapeutic effects of 2-Methoxyestradiol on Monocrotaline-Induced pulmonary hypertension and vascular remodelling. Prilozi, 2010. 31(1): p. 279-95."},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_028_w2aab3b7b6b1b6b1ab1ac28Aa","doi-asserted-by":"crossref","unstructured":"28. Tofovic, S.P., et al., Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling. J Cardiovasc Pharmacol, 2010. 56(5): p. 475-83.10.1097\/FJC.0b013e3181f215e720881615","DOI":"10.1097\/FJC.0b013e3181f215e7"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_029_w2aab3b7b6b1b6b1ab1ac29Aa","doi-asserted-by":"crossref","unstructured":"29. Havill, A.M., et al., alpha-Naphthylthiourea produces dose-dependent lung vascular injury in sheep. Am J Physiol, 1982. 243(4): p. H505-11.10.1152\/ajpheart.1982.243.4.H5056812437","DOI":"10.1152\/ajpheart.1982.243.4.H505"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_030_w2aab3b7b6b1b6b1ab1ac30Aa","doi-asserted-by":"crossref","unstructured":"30. Hesse, F.E. and C.G. Loosli, The lining of the alveoli in mice, rats, dogs, and frogs following acute pulmonary edema produced by ANTU poisoning. Anat Rec, 1949. 105(2): p. 299-323, incl 6 pl.10.1002\/ar.109105020715398723","DOI":"10.1002\/ar.1091050207"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_031_w2aab3b7b6b1b6b1ab1ac31Aa","unstructured":"31. Michel, R.P., Lung microvascular permeability to dextran in alpha-naphthylthiourea-induced edema. Sites of filtration, patterns of accumulation, and effects of fixation. Am J Pathol, 1985. 119(3): p. 474-84."},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_032_w2aab3b7b6b1b6b1ab1ac32Aa","doi-asserted-by":"crossref","unstructured":"32. Verenich, S. and P.M. Gerk, Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm, 2010. 7(6): p. 2030-9.10.1021\/mp100190f305989920831190","DOI":"10.1021\/mp100190f"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_033_w2aab3b7b6b1b6b1ab1ac33Aa","doi-asserted-by":"crossref","unstructured":"33. Berg, D., R. Sonsalla, and E. Kuss, Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Co-penh), 1983. 103(2): p. 282-8.10.1530\/acta.0.10302826858558","DOI":"10.1530\/acta.0.1030282"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_034_w2aab3b7b6b1b6b1ab1ac34Aa","unstructured":"34. Tofovic SP, Jackson EK, Piche C, Pharmacokinetics and safety of a subcutaneously injected long-acting formulation of 2-methoxyestradiol(2ME) in healthy volunteers. Basic & Clinical Pharmacology & Toxicology, 2009. 105: p. 107."},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_035_w2aab3b7b6b1b6b1ab1ac35Aa","doi-asserted-by":"crossref","unstructured":"35. Ba, M. and Y. Duan, Advance of 2-methoxyestradiol as a promising anticancer agent for cancer therapy. Future Med Chem, 2020. 12(4): p. 273-275.10.4155\/fmc-2019-025831983223","DOI":"10.4155\/fmc-2019-0258"},{"key":"2026071211372960533_j_prilozi-2021-0003_ref_036_w2aab3b7b6b1b6b1ab1ac36Aa","doi-asserted-by":"crossref","unstructured":"36. Kumar, B.S., et al., Recent Advances in chemistry and pharmacology of 2-methoxyestradiol: An anticancer investigational drug. Steroids, 2016. 110: p. 9-34.10.1016\/j.steroids.2016.03.01727020471","DOI":"10.1016\/j.steroids.2016.03.017"}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2021-0003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:55:32Z","timestamp":1783896932000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2021-0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,4,23]]},"published-print":{"date-parts":[[2021,4,1]]}},"alternative-id":["10.2478\/prilozi-2021-0003"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2021-0003","relation":{},"ISSN":["1857-8985","1857-9345"],"issn-type":[{"value":"1857-8985","type":"electronic"},{"value":"1857-9345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}